| 1 |
FriedensteinAJ, Petrakova KV, Kurolesova AI,et al. Heterotopic transplants of bone marrow[J]. Transplantation, 1968, 6(2):230-247.
|
| 2 |
Caplan AI, Bruder SP. Mesenchymal stem cells: building blocks for molecular medicine in the 21st century[J]. Trends Mol Med, 2001, 7(6):259-264.
|
| 3 |
Di Trapani M, Bassi G, Midolo M, et al. Differential and transferable modulatory effects of mesenchymal stromal cell-derived extracellular vesicles on T, B and NK cell functions[J]. Sci Rep, 2016, 6:24120.
|
| 4 |
Zhao K, Lou R, Huang F, et al. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2015, 21(1):97-104.
|
| 5 |
Gotherstrom C, Westgren M, Shaw SW, et al. Pre-and postnatal transplantation offetal mesenchymal stem cells in osteogenesis imperfecta:a two-center experience[J]. Stem Cells Transl Med, 2014, 3(2):255-264.
|
| 6 |
Dalal J, Gandy K, Domen J. Role of mesenchymal stem cell therapy in Crohn's disease[J]. Pediatr Res 2012,71(4):445-451.
|
| 7 |
Shrestha B, Coykendall K, Li YC, et al. Repair of injured spinal cord using biomaterial scaffolds and stem cells[J]. Stem Cell Res Ther, 2014, 5(4):91.
|
| 8 |
Ankrum J, Karp JM. Mesenchymal stem cell therapy: Two steps forward, one step back[J]. Trends Mol Med, 2010, 16(5):203-209.
|
| 9 |
Gao F, Chiu SM, Motan D, et al. Mesenchymal stem cells and immunomodulation: current status and future prospects[J]. Cell Death Dis, 2016, 7:e2062.
|
| 10 |
Munir H, Luu NT, Clarke LS, et al. Comparative ability of mesenchymal stromal cells from different tissues to limit neutrophil recruitment to inflamed endothelium [J]. PLoS One, 2016, 11(5):e0155161.
|
| 11 |
Luu NT, Mcgettrick HM, Buckley CD, et al. Crosstalk between mesenchymal stem cells and endothelial cells leads to downregulation of Cytokine-Induced leukocyte recruitment[J]. Stem Cells, 2013, 31(12):2690-2702.
|
| 12 |
Mantovani A. MSCs, macrophages, and cancer: a dangerous Menage-a-Trois[J]. Cell Stem Cell, 2012, 11(6):730-732.
|
| 13 |
Eggenhofer E, Hoogduijn MJ. Mesenchymal stem cell-educated macrophages[J]. Transplant Res, 2012, 1(1):12.
|
| 14 |
Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation[J]. Cell Stem Cell, 2013, 13(4):392-402.
|
| 15 |
Mantovani A, Biswas SK, Galdiero MR, et al. Macrophage plasticity and polarization in tissue repair and remodelling[J]. J Pathol, 2013, 229(2):176-185.
|
| 16 |
François M, Romieu-Mourez R, Li M, et al. Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation[J]. Mol Ther, 2012, 20(1):187-195.
|
| 17 |
Li W, Ren G, Huang Y, et al. Mesenchymal stem cells: a double-edged sword in regulating immune responses[J]. Cell Death Differ, 2012, 19(9):1505-1513.
|
| 18 |
Burr SP, Dazzi F, Garden OA. Mesenchymal stromal cells and regulatory T cells: the Yin and Yang of peripheral tolerance?[J]. Immunol Cell Biol, 2013, 91(1):12-18.
|
| 19 |
Stagg J, Galipeau J. Mechanisms of immune modulation by mesenchymal stromal cells and clinical translation[J]. Curr Mol Med, 2013, 13(5):856-867.
|
| 20 |
Van Den Berk LC, Jansen BJ, Snowden S, et al. Cord blood mesenchymal stem cells suppress DC-T Cell proliferation via prostaglandin B2[J]. Stem Cells Dev, 2014, 23(14):1582-1593.
|
| 21 |
Li M, Sun X, Kuang X, et al. Mesenchymal stem cells suppress CD8+ T cell-mediated activation by suppressing natural killer group 2, member D protein receptor expression and secretion of prostaglandin E2, indoleamine 2, 3-dioxygenase and transforming growth factor-beta[J]. Clin Exp Immunol, 2014, 178(3):516-524.
|
| 22 |
Liu LY, Song HF, Duan HJ, et al. TSG-6 secreted by human umbilical cord-MSCs attenuates severe burn-induced excessive inflammation via inhibiting activations of P38 and JNK signaling[J]. Sci Rep, 2016, 6:30121.
|
| 23 |
Danchuk S, Ylostalo JH, Hossain F, et al. Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-alpha-induced protein 6[J]. Stem Cell Res Ther, 2011, 2(3):1-15.
|
| 24 |
Foskett AM, Bazhanov N, Ti XY, et al. Phase-directed therapy: TSG-6 targeted to early inflammation improves bleomycin-injured lungs[J]. Am J Physiol Lung Cell Mol Physiol, 2014, 306(2):L120-L131.
|
| 25 |
Wang SS, Hu SW, Zhang QH, et al. Mesenchymal stem cells stabilize atherosclerotic vulnerable plaque by Anti-Inflammatory properties[J]. PLoS One, 2015, 10(8):e0136026.
|
| 26 |
Choi H, Lee RH, Bazhanov N, et al. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-kappa B signaling in resident macrophages[J]. Blood, 2011, 118(2):330-338.
|
| 27 |
Watanabe J, Shetty AK, Hattiangady B, et al. Administration of TSG-6 improves memory after traumatic brain injury in mice[J]. Neurobiol Dis, 2013, 59:86-99.
|
| 28 |
Chen X, Zhang ZY, Zhou H, et al. Characterization of mesenchymal stem cells under the stimulation of Toll- like receptor agonists[J]. Dev Growth Differ, 2014, 56(3):233-244.
|
| 29 |
Waterman RS, Tomchuck SL, Henkle SL, et al. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype[J]. PLoS One, 2010, 5(4):e10088.
|
| 30 |
Prockop DJ. Concise review:two negative feedback loops place mesenchymal stem/stromal cells at the center of early regulators of inflammation[J]. Stem Cells, 2013, 31(10):2042-2046.
|
| 31 |
Keating A. Mesenchymal stromal cells: new directions[J]. Cell Stem Cell, 2012, 10(6):709-716.
|
| 32 |
Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system[J]. Nat Rev Immunol, 2012, 12(5):383-396.
|
| 33 |
Delarosa O, Dalemans W, Lombardo E. Toll-like receptors as modulators of mesenchymal stem cells[J]. Front Immunol, 2012, 3:182.
|
| 34 |
Raicevic G, Rouas R, Najar M, et al. Inflammation modifies the pattern and the function of Toll-like receptors expressed by human mesenchymal stromal cells[J]. Hum Immunol 2010,71(3):235-244.
|